Rates of serious infections, opportunistic infections, inflammatory bowel disease, and malignancies in subjects receiving etanercept vs. Controls from clinical trials in ankylosing spondylitis: A pooled analysis

Scandinavian Journal of Rheumatology

Volumn 43, Issue 1, 2014, Pages 49-53

  Van Der Heijde, D ^a   Zack, D ^b   Wajdula, J ^c   Sridharan, S ^c   Koenig, A S ^c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b AMGEN INC   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; SALAZOSULFAPYRIDINE;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; DATA BASE; DISEASE DURATION; DRUG EXPOSURE; DRUG SAFETY; FEMALE; HUMAN; INFECTION; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SERIOUS INFECTION; SKIN CANCER; STANDARDIZED INCIDENCE RATIO;

ADULT; ANTIRHEUMATIC AGENTS; CLINICAL TRIALS AS TOPIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN G; INCIDENCE; INFECTION; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; NEOPLASMS; OPPORTUNISTIC INFECTIONS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 84893018372     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2013.834961     Document Type: Article

References (18)

1. Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2010;2:CD008794.
2. van Luijn JC, Danz M, Bijlsma JW, Gribnau FW, Leufkens HG. Post-approval trials of new medicines: widening use or deepening knowledge? Analysis of 10 years of etanercept. Scand J Rheumatol 2011;40:183-91.
3. Strangfeld A, Listing J. Infection and musculoskeletal conditions: bacterial and opportunistic infections during anti-TNF therapy. Best Pract Res Clin Rheumatol 2006;20:1181-95. (Pubitemid 44774817)
4. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. J Am Med Assoc 2006;295:2275-85. (Pubitemid 43736578)
5. Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis 2009;68:1177-83.
6. Braun J, Huang F, Burgos-Vargas R, van der Horst-Bruinsma IE, Freundlich B, Vlahos B, et al. Assessment of clinical efficacy in a randomized, double-blind study of etanercept and sulfasalazine in patients with ankylosing spondylitis. Arthritis Rheum 2008;58 (Suppl 9):S415.
7. Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo- Repo M, et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004;63:1594-600. (Pubitemid 39573687)
8. Davis JC Jr, van der Heijde DM, Braun J, Dougados M, Clegg DO, Kivitz AJ, et al. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 2008;67:346-52. (Pubitemid 351281269)
9. Dijkmans B, Emery P, Hakala M, Leirisalo-Repo M, Mola EM, Paolozzi L, et al. Etanercept in the long-term treatment of patients with ankylosing spondylitis. J Rheumatol 2009;36:1256-64.
10. Martin-Mola E, Sieper J, Leirisalo-Repo M, Dijkmans BA, Vlahos B, Pedersen R, et al. Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis. Clin Exp Rheumatol 2010;28:238-45.
11. Healey EL, Haywood KL, Jordan KP, Garratt A, Packham JC. Impact of ankylosing spondylitis on work in patients across the UK. Scand J Rheumatol 2011;40:34-40.
12. Davis JC Jr, van der Heijde D, Braun J, DougadosM, Cush J, Clegg DO, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-6. (Pubitemid 37409337)
13. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002;346:1349-56. (Pubitemid 34754607)
14. van der Heijde D, Da Silva JC, Dougados M, Geher P, van der Horst-Bruinsma I, Juanola X, et al. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:1572-7. (Pubitemid 44799667)
15. Sahai H, Khurshid A. Statistics in epidemiology: methods, techniques, and applications. Boca Raton, FL: CRC Press, 1996.
16. Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2006;2:602-10. (Pubitemid 44650948)
17. Braun J, Baraliakos X, Listing J, Davis J, van der Heijde D, Haibel H, et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 2007;57:639-47. (Pubitemid 46764055)
18. Gottlieb AB, Gordon K, Giannini EH, Mease P, Li J, Chon Y, et al. Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications. J Drugs Dermatol 2011;10:289-300.